{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:26:59Z","timestamp":1747171619769,"version":"3.40.5"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.thromres.2015.07.006","type":"journal-article","created":{"date-parts":[[2015,7,10]],"date-time":"2015-07-10T21:57:00Z","timestamp":1436565420000},"page":"691-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The JAK2 V617F mutational status and allele burden \u2013 authors\u2019 reply"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4824-8131","authenticated-orcid":false,"given":"Martyna","family":"Borowczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzena","family":"Wojtaszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lewandowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Lehmann-Kopyd\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Kroll-Balcerzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Balcerzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Iwo\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Michalak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieczys\u0142aw","family":"Komarnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2015.07.006_bb0005","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.thromres.2015.07.008","article-title":"The JAK2 V617F mutational status and allele burden","volume":"136","author":"Liang","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2015.07.006_bb0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"Borowczyk","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2015.07.006_bb0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2015.07.006_bb0020","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2015.07.006_bb0025","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.thromres.2015.07.006_bb0030","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20years. Gruppo Italiano Studio Policitemia","volume":"123","author":"Gis","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.thromres.2015.07.006_bb0035","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.07.006_bb0040","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3324\/haematol.13869","article-title":"Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia","volume":"94","author":"De Stefano","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2015.07.006_bb0045","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2015.07.006_bb0050","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/leu.2013.74","article-title":"Problems and pitfalls regarding WHO-defined diagnosis of early\/prefibrotic primary myelofibrosis versus essential thrombocythemia","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.thromres.2015.07.006_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.2012.09179.x","article-title":"Guideline for the diagnosis and management of myelofibrosis","volume":"158","author":"Reilly","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2015.07.006_bb0060","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/PAI.0000000000000000","article-title":"Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis","volume":"22","author":"Sangle","year":"2014","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.thromres.2015.07.006_bb0065","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/asheducation.V2012.1.561.3807838","article-title":"The spectrum of JAK2-positive myeloproliferative neoplasms","volume":"2012","author":"Kiladjian","year":"2012","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.thromres.2015.07.006_bb0070","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.24037","article-title":"New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2015.07.006_bb0075","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11899-014-0228-z","article-title":"Epidemiology of MPN: what do we know?","volume":"9","author":"Anderson","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.thromres.2015.07.006_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-015-1808-y","article-title":"The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis","author":"Qin","year":"2015","journal-title":"Int. J. Hematol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384815300608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384815300608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T22:22:55Z","timestamp":1599258175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384815300608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0049384815300608"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2015.07.006","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The JAK2 V617F mutational status and allele burden \u2013 authors\u2019 reply","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2015.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}